ALAlfonso Leal-Cerro

Alfonso Leal-Cerro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfonso Leal-Cerro has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Chronic adult‐onset of growth hormone/IGF‐I hypersecretion improves cognitive functions and LTP and promotes neuronal differentiation in adult rats

    by Juan Francisco Martín‐Rodríguez, Víctor Darío Ramos‐Herrero, Gloria G. Parras, Álvaro Flores‐Martínez, Ainara Madrazo‐Atutxa, David A. Cano, Agnès Gruart, José María Delgado‐García, Alfonso Leal‐Cerro, Rocío Leal‐Campanario

    Aim: Besides their metabolic and endocrine functions, the growth hormone (GH) and its mediated factor, the insulin‐like growth factor I (IGF‐I), have been implicated in different brain functions, including neurogenesis. Long‐lasting elevated GH and IGF‐I levels result in non‐reversible somatic, endocrine and metabolic morbidities. However, the subcutaneous implantation of the GH‐secreting (GH‐S) GC cell line in rats leads to the controllable over‐secretion of GH and elevated IGF‐I levels, allowing the experimental study of their short‐term effects on brain functions.Methods: Adult rats were implanted with GC cells and checked 10 weeks later, when a GH/IGF‐I‐secreting tumour was already formed.Results: Tumour‐bearing rats acquired different operant conditioning tasks faster and better than controls and tumour‐resected groups. They also presented better retentions of long‐term memories in the passive avoidance test. Experimentally evoked long‐term potentiation (LTP) in the hippocampus was also larger and longer lasting in the tumour bearing than in the other groups. Chronic adult‐onset of GH/IGF‐I hypersecretion caused an acceleration of early progenitors, facilitating a faster neural differentiation, maturation and integration in the dentate gyrus, and increased the complexity of dendritic arbours and spine density of granule neurons.Conclusion: Thus, adult‐onset hypersecretion of GH/IGF‐I improves neurocognitive functions, long‐term memories, experimental LTP and neural differentiation, migration and maturation.


  • The Effects of Bariatric Surgery-Induced Weight Loss on Adipose Tissue in Morbidly Obese Women Depends on the Initial Metabolic Status

    by Natalia Moreno-Castellanos, Rocío Guzmán-Ruiz, David A. Cano, Ainara Madrazo-Atutxa, Juan R. Peinado, Jose L. Pereira-Cunill, Pedro Pablo García-Luna, Salvador Morales-Conde, Maria Socas-Macias, Rafael Vázquez-Martínez, et al.

    Adipose tissue (AT) dysfunction in obesity is commonly linked to insulin resistance and promotes the development of metabolic disease. Bariatric surgery (BS) represents an effective strategy to reduce weight and to improve metabolic health in morbidly obese subjects. However, the mechanisms and pathways that are modified in AT in response to BS are not fully understood, and few information is still available as to whether these may vary depending on the metabolic status of obese subjects. Abdominal subcutaneous adipose tissue (SAT) samples were obtained from morbidly obese women (n = 18) before and 13.3 ± 0.37 months after BS. Obese women were stratified into two groups: normoglycemic (NG; Glu < 100 mg/dl, HbA1c n = 9/group). A multi-comparative proteomic analysis was employed to identify differentially regulated SAT proteins by BS and/or the degree of insulin sensitivity. Serum levels of metabolic, inflammatory, and anti-oxidant markers were also analyzed. Before surgery, NG and IR subjects exhibited differences in AT proteins related to inflammation, metabolic processes, the cytoskeleton, and mitochondria. BS caused comparable weight reductions and improved glucose homeostasis in both groups. However, BS caused dissimilar changes in metabolic enzymes, inflammatory markers, cytoskeletal components, mitochondrial proteins, and angiogenesis regulators in NG and IR women. BS evokes significant molecular rearrangements indicative of improved AT function in morbidly obese women at either low or high metabolic risk, though selective adaptive changes in key cellular processes occur depending on the initial individual’s metabolic status.


  • Differential in vitro response to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures

    by Alejandro Ibanez-Costa, Manuel David Gahete, Luis Jimenez-Reina, Esther Rivero-Cortes, Laura Maria Lopez-Sanchez, Maria Angeles Galvez, la Riva Andres de, Pedro Benito-Lopez, Eva Venegas-Moreno, Japon Miguel Angel, et al.

    Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireotide responsiveness, we have established a reliable methodology to evaluate, in parallel, the in vitro response to octreotide and pasireotide using primary PA cultures by assessing sst-signaling (free-cytosolic (Ca2+) kinetics) and secretory and proliferative responses. In addition, expression of pituitary hormones and ssts using RT-PCR and, hormonal secretion by immuno-blotting was assessed. A total of 44 samples (16 somatotropinomas, 6 corticotropinomas, 5 prolactinomas, 15 non-functioning PA (NFPA) and 2 normal pituitaries) were evaluated. Octreotide and pasireotide treatment decrease (Ca2+) kinetics in 13/16 and 7/16 somatotropinomas respectively; while both SSA similarly inhibited GH secretion and proliferation. Inhibition of (Ca2+) kinetics in response to octreotide and pasireotide were observed in 2/6 and 4/6 corticotropinomas, although it only occurs in a small proportion of cells, whereas ACTH release was not significantly affected. In prolactinomas, only octreotide inhibited (Ca2+) kinetics. In NFPA, both SSA moderately decreased (Ca2+) kinetics (few responsive PA, with moderate inhibition and small proportion of responsive cells), while surprisingly, both SSA stimulated cell proliferation in a considerable proportion of PA. Finally, octreotide did not alter (Ca2+) kinetics in normal pituitary cultures while, pasireotide exerted a faint inhibitory response. The differential response to octreotide and/or pasireotide could not be explained by significant differences in sst-expression pattern between responsive and non-responsive PA. Altogether, our data indicate the existence of a differential in vitroresponse to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures and therefore, further studies are necessary to unveil the key factors involved in this differential responsiveness to SSA.

  • Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease

    by Alfonso Leal-Cerro, Juan Francisco Martín-Rodríguez, Alejandro Ibáñez-Costa, Ainara Madrazo-Atutxa, Eva Venegas-Moreno, Antonio León-Justel, Natividad García-Hernández, Raúl M. Luque, Justo P. Castaño, David A. Cano, et al.


  • Open Access

    Neurocognitive Function in Acromegaly after Surgical Resection of GH-Secreting Adenoma versus Naïve Acromegaly

    by Juan Francisco Martín-Rodríguez, Ainara Madrazo-Atutxa, Eva Venegas-Moreno, Pedro Benito-López, María Ángeles Gálvez, David A. Cano, Francisco J. Tinahones, Elena Torres-Vela, Alfonso Soto-Moreno, Alfonso Leal-Cerro

    Patients with active untreated acromegaly show mild to moderate neurocognitive disorders that are associated to chronic exposure to growth hormone (GH) and insulin-like growth factor (IGF-I) hypersecretion. However, it is unknown whether these disorders improve after controlling GH/IGF-I hypersecretion. The aim of this study was to compare neurocognitive functions of patients who successfully underwent GH-secreting adenoma transsphenoidal surgery (cured patients) with patients with naive acromegaly. In addition, we wanted to determine the impact of different clinical and biochemical variables on neurocognitive status in patients with active disease and after long-term cure. A battery of six standardized neuropsychological tests assessed attention, memory and executive functioning. In addition, a quantitative electroencephalography with Low-Resolution Electromagnetic Tomography (LORETA) solution was performed to obtain information about the neurophysiological state of the patients. Neurocognitive data was compared to that of a healthy control group. Multiple linear regression analysis was also conducted using clinical and hormonal parameters to obtain a set of independent predictors of neurocognitive state before and after cure. Both groups of patients scored significantly poorer than the healthy controls on memory tests, especially those assessing visual and verbal recall. Patients with cured acromegaly did not obtain better cognitive measures than naïve patients. Furthermore memory deficits were associated with decreased beta activity in left medial temporal cortex in both groups of patients. Regression analysis showed longer duration of untreated acromegaly was associated with more severe neurocognitive complications, regardless of the diagnostic group, whereas GH levels at the time of assessment was related to neurocognitive outcome only in naïve patients. Longer duration of post-operative biochemical remission of acromegaly was associated with better neurocognitive state. Overall, this data suggests that the effects of chronic exposure to GH/IGF-I hypersecretion could have long-term effects on brain functions.


  • Evaluation of the efficacy of midnight salivary cortisol plus dexamethasone suppression test as screening for the diagnosis of hypercortisolism within an at-risk population

    by Alfonso Leal-Cerro, Ainara Madrazo-Atutxa, Juan Garcia-Arnes, Cristina Lamas-Oliveira, Mauro Boronat-Cort, Juan A Lillo, Carmen Fajardo, Eulalia Urgell-Rull, Javier Salvador, Isabel Salinas, et al.

    Introduction: Endogenous Cushing’s syndrome (CS) is a rare, infradiagnosed and severe disease that carries high morbidity and mortality. Delays in treatment initiation reduce reversibility of symptoms and increase mortality rate. Current gold standard for screening, 24 h urinary free cortisol, has a low reproducibility and specificity, and sampling is complicated. Midnight salivary cortisol (MSVC) determination is considered an easy and cheap test. We intend to assess its feasibility combined with suppression test to screen CS. This initiative has been developed by the Cushing’s disease (CD) working group, member of the Sociedad Española de Endocrinología y Nutrición (SEEN) and supported by Novartis. Methods/design: Epidemiological cross-sectional study to asses MSVC plus suppression test. Secondary objectives are to describe the prevalence of CS and CD in the studied population. Patients will be performed the two tests, results from both, clinical characteristics and final diagnosis of CS or CD will be recorded. Results: This project, named CRIbado en SALIva De Alteraciones del cortisol (CRISÁLIDA) was initiated on November 2012, with 13 participating sites accross Spain. Sample size will be 609 patients and results from an interim analysis are expected on April 2013. Study population includes a group of patients considered at risk of presenting high cortisol levels, presenting at least 2 of the following symptoms: obesity (BMI >30), hard to control hypertension (SBP >140 and DBP >90 mmHg, >2 drugs), poorly controlled diabetes (HbA1c >7.0%), severe osteoporosis (−2.5 S.D. in T-score) or virilization syndrome. Exclusion criteria: pregnancy, age >70 years, glucocorticoid treatment, CS or CD diagnosis, chronic renal impairment or hepatopathy, between others. Conclusion: CRISÁLIDA is a multicentric project designed to identify most relevant characteristics of an at-risk population and to move forward in the screening and diagnosis of a rare disease (CD).

  • A Novel Human Ghrelin Variant Containing Intron 2 (In2-Ghrelin) Is Present in Normal and Tumoral Pituitaries: Potential Pathological Relevance

    by Raul M Luque, Manuel D Gahete, Jose Cordoba-Chacon, Laura Lopez-Sanchez, Luis Jimenez-Reina, Miguel A Japon, Pedro Benito, Alfonso Leal-Cerro, Michael D Culler, Rhonda D Kineman, et al.

    Ghrelin is a multifunctional hormone expressed in multiple tissues including the hypotalamo-pituitary unit, wherein it modulates diverse neuroendocrine secretions. We recently identified a ghrelin splice variant in mouse, In2-ghrelin, and showed that, compared native ghrelin, it is differentially distributed in various tissues (e.g. In2-ghrelin is far more abundant in pituitary), and is divergently regulated under extreme metabolic conditions, thereby supporting its putative pathophysiological relevance. Here, we have identified and cloned a new human In2-ghrelin variant counterpart, and have investigated its presence in normal and tumoral pituitary, as well as its involvement in relevant processes, including hormone secretion or cell proliferation. Like in native ghrelin, predicted human In2-ghrelin peptide sequence posseses two cleavage sites where it can be cleaved by convertases to generate two mature products. Since most known ghrelin actions, especially at the pituitary, require its acylation, and In2-ghrelin retains Ser3 acylation site, we synthesized these two predicted In2-ghrelin peptides including it acyl-modification. As observed in mice, human In2-ghrelin is expressed at higher levels than native ghrelin in the pituitary. Remarkably, mRNA of In2-ghrelin variant was markedly overexpressed in various types of pituitary tumors, including non-functioning pituitary adenomas (NFPA), corticotropinomas and somatotoprinomas. Of note, somatotropinomas presenting extension into sphenoid sinus expressed higher levels of In2-ghrelin. Functional studies revealed that both In2-ghrelin peptides are able to activate key intracellular signals (i.e. Ca2+) in cells derived from NFPA and ACTH-omas in vitro. This was associated with an increase of ACTH secretion in adenoma cells from Cushing's patients. Moreover, transfection with In2-ghrelin and/or treatment with In2-ghrelin peptides caused an increase in the proliferation rate of cell cultures derived from these three types of pituitary tumors. Taken together, our results provide primary evidence that In2-ghrelin is a potential novel element of the ghrelin family with a plausible pathophysiological role in human pituitary function, since it is expressed in normal pituitaries and overexpressed in adenomas, wherein it can regulate hormone secretion and/or tumoral cell proliferation. Sources of Research Support: FI06/00804 (to J.C.-C.), FPU-AP20052473 (to M.D.G.); BFU2010-19300 and CTS-5051 (to J.P.C.), R01DK030677 and Veterans Affairs Merit Award (to R.D.K.) and Grants RYC-2007-00186, BFU2008-01136/BFI (to R.M.L.). Nothing to Disclose: RML, MDG, JC-C, LL-S, LJ-R, MAJ, PB, AL-C, MDC, RDK, JPC

  • Cognitive Status in Acromegaly: Possible Recovery after Successful Treatment

    by Juan Francisco Martin-Rodriguez, Ainara Madrazo-Atutxa, Alfonso Soto-Moreno, Eva Venegas-Moreno, Elena Torres-Vela, Pedro Benito-Lopez, Maria Angeles Galvez, Francisco J Tinahones, Alfonso Leal-Cerro

    De novo acromegalic patients show neurocognitive impairment associated to high GH and IGF-I levels1. It has been suggested that this impairment might be a consequence of lasting exposure to GH and IGF-I excess on the central nervous system 1-3. Nevertheless, it remains to be determined whether neurocognitive problems are still present when the disease is cured or controlled with drugs. This research aims to study the neurocognitive state of acromegalic patients after cure and patients with successful pharmacological control of acromegaly. Cognitive functions, emotional status and quality of life (QoL) were assessed in fifteen patients cured of acromegaly (10 women, median age = 50.93) and 15 patients with pharmacologically control of acromegaly (somatostin analogs) (10 women, median age = 48.19). The criteria stablished for cure after pituitary surgery were normal IGF-I levels for age and gender and a GH nadir < 1 ng/mL after an oral glucose tolerance test. The criteria stablished for good control of acromegaly were normal IGF-I levels for age and gender and a basal GH < 2 ng/ml. These patients' data were compared to two age- and gender-matched additional groups, comprised of 15 patients with non-treated active acromegaly and 15 healthy controls. No difference was observed in tests assessing attention, verbal skills and executive functions among the different groups. However, significant differences were found in memory tests (all Ps < 0.01). Concretely, patients with active non-treated acromegaly and patients with good pharmacologically control performed worse in working memory and long-term memory than healthy subjects and cured patients. Further analyses showed a significant correlation between emotional/QoL and severity of memory impairment in pharmacologically controlled patients. In the active non-treated group, no correlation between QoL, depression and severity of memory impairment was observed. Patients with cured acromegaly did not differ from healthy subjects in cognitive functions and emotional/QoL status. Our results confirm memory impairment in active acromegaly that could be due to GH and IGF-I excess. In addition, our findings suggest a good recovery of cognitive impairment after cure of acromegaly while patients with good pharmacological control of the disease show similar memory impairment than that observed in de novo patients. (1) Leon-Carrion J et al., J Clin Endocrinol Metab 2010; 95: 4367 (2) Tanriverdi F et al., Growth Horm IGF Res 2009; 19: 24 (3) Tiemensma J et al., J Clin Endocrinol Metab 2011; 95: E392 Sources of Research Support: Grant from Novartis Oncology. We are indebted to Dr. Monserrat Gilabert for her help in editing the Nothing to Disclose: JFM-R, AM-A, AS-M, EV-M, ET-V, PB-L, MAG, FJT, AL-C

  • Evidence of Cognitive and Neurophysiological Impairment in Patients with Untreated Naive Acromegaly

    by José Leon-Carrion, Juan Francisco Martin-Rodriguez, Ainara Madrazo-Atutxa, Alfonso Soto-Moreno, Eva Venegas-Moreno, Elena Torres-Vela, Pedro Benito-López, Maria Ángeles Gálvez, Francisco J. Tinahones, Alfonso Leal-Cerro